10-Q: Aethlon Medical Reports Q3 2025 Results, Highlights Progress in Clinical Trials and Financial Position

Aethlon Medical's Q3 2025 report details ongoing clinical trials for the Hemopurifier, recent equity transactions, and financial results, while acknowledging the need for additional funding.

Summary

• Aethlon Medical, Inc. filed its Form 10-Q for the quarterly period ended December 31, 2024.
• The company is focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device.
• The Hemopurifier has Breakthrough Device designation from the FDA for cancer and life-threatening viruses.
• Clinical trials for the Hemopurifier are underway in Australia and India, focusing on cancer patients.
• The first patient in the Australian trial was treated in late January 2025 with no adverse events.
• A COVID-19 clinical trial in India was terminated due to lack of patient enrollment.
• The company is also exploring the Hemopurifier's potential in organ transplantation.
• Aethlon effected a 1-for-10 reverse stock split on October 4, 2023.
• The company incurred a net loss of $1,754,783 for the three months ended December 31, 2024, and $7,133,196 for the nine months ended December 31, 2024.
• A public offering in May 2024 generated net proceeds of approximately $3.5 million.
• Warrant exercises in June 2024 provided an additional $1,844,400.
• The company's cash balance as of December 31, 2024, was $4,825,387.
• Aethlon expects existing cash will not be sufficient to fund operations for the next twelve months and will require additional financing.
• The company is monitoring the impact of global events like inflation and military conflicts on its business.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is progress in clinical trials and some positive financial events, the company faces significant financial challenges and risks.

Positives

• The Hemopurifier has received Breakthrough Device designation from the FDA for two indications.
• Clinical trials are progressing in Australia and India.
• The first patient in the Australian trial was successfully treated.
• A public offering and warrant exercises have provided additional capital.
• The company is exploring new applications for the Hemopurifier in organ transplantation.

Negatives

• Aethlon Medical has incurred significant losses and expects to continue incurring losses.
• The company terminated its COVID-19 clinical trial in India due to lack of enrollment.
• Aethlon anticipates needing additional financing to sustain operations for the next twelve months.
• The company has a material weakness in its internal control over financial reporting related to segregation of duties within its financial systems.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• Delays in clinical trials could jeopardize regulatory approval and operations.
• The company faces intense competition in the medical device industry.
• The Hemopurifier technology may become obsolete.
• Failure to comply with regulations could delay or prevent commercialization.
• The company may face challenges attracting and retaining executive management and directors.
• Global economic conditions and disruptions in financial markets could adversely impact the ability to raise additional funds.

Future Outlook

Aethlon expects to continue incurring increasing negative cash flows and net losses for the foreseeable future and will need to raise additional capital through equity and/or debt financing.

Industry Context

Aethlon Medical operates in the competitive medical device industry, focusing on immunotherapeutic devices. The company's Hemopurifier targets unmet needs in cancer, viral infections, and organ transplantation, aligning with broader trends in personalized medicine and innovative therapies. The Breakthrough Device designation from the FDA underscores the potential significance of the Hemopurifier in addressing life-threatening conditions.

Comparison to Industry Standards

• It is difficult to compare Aethlon's results to industry standards due to the unique nature of its Hemopurifier device and its focus on specific applications.
• However, the company's financial performance can be compared to other small-cap biotechnology companies in the development stage.
• Aethlon's cash burn rate and need for additional financing are common challenges for companies in this sector.
• The success of Aethlon's clinical trials and regulatory approvals will be critical in determining its long-term viability and competitiveness.

Related Party Transactions

• During the three-months ended December 31, 2024, we accrued $ 68,250 for board fees and paid fees of $ 68,250 owed to our non-employee directors for services in the current and prior quarter respectively.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees' job security is dependent on the company's ability to secure additional funding.
• Patients may benefit from the potential of the Hemopurifier to treat life-threatening conditions.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• Continue clinical trials in Australia and India.
• Pursue regulatory approvals for the Hemopurifier.
• Explore potential applications in organ transplantation.
• Secure additional financing to sustain operations.

Key Dates